Editorial

• Volume 9 Number 11/12 November/December 2008

• i-BASE APPEAL

Conference reports

• 48th Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25-28 October 2008, Washington DC

• Antiretroviral Pregnancy Registry finds no increase in congenital anomalies with exposure to tenofovir

• No association between maternal antiretrovirals in pregnancy and congenital anomalies

• Pharmacokinetics of saquinavir/ritonavir in pregnancy

• Course of labour in pregnant HIV-positive women with no contraindication for vaginal delivery

• Four weeks of antiretroviral prophylaxis is sufficient for HIV-exposed infants

• HAART suppresses genital tract HIV shedding in HIV/HSV co-infected women

• Efavirenz significantly reduces levels of some oral contraceptives

• Lack of efficacy of isoniazid (INH) prophylaxis and PK evaluation in South African infants

• 48-week data for darunavir/ritonavir (DRV/r) in treatment-experienced children and adolescents

• Greater lipodystrophy risk in older US children with low viral load

• Studies of pipeline drugs: RDEA806, PRO140, bevirimat, elvucitabine

• Maraviroc trial results reanalysed using more sensitive CCR5 tropism test

• Other antiretroviral studies at ICAAC

• High rate of rash in HIV-negative volunteers combining raltegravir and darunavir

• Bone loss in SMART study

• Parathyroid hormone and vitamin D levels in patients using tenofovir

• Haemoglobin A1c (HbA1c) may underestimate glycaemia in patients with diabetes on HIV therapy

• Statin use in HIV-positive patients

• HIV reinfection reported in 10% of couples in Zambian study

• Drug interaction studies with approved drugs

• Non alcoholic fatty liver disease (NAFLD) is common among HIV-positive patients

Antiretrovirals

• FDA approves new paediatric AZT dosing

• US revisions to darunavir label include once-daily indication for naïve patients

• Baseline renal insufficiency and mortality risk in HIV-positive adults in Zambia

• Inflammatory and coagulation biomarkers linked to mortality in large treatment interruption trial

Guidelines

• IAS (USA) resistance guidelines

• BHIVA guidelines for immunisation of HIV-infected adults

• 2008 European Guidelines (EACS) online

• US guidelines updated – November 2008

PMTCT and maternal health

• OCTANE Trial DSMB finds ritonavir-boosted lopinavir superior to nevirapine in HIV-positive women previously exposed to single dose nevirapine

• Antiretroviral therapy in pregnant women and pregnancy outcomes in Abidjan, Cote D’Ivoire

Paediatric care

• Antiretroviral therapy in HIV-positive children in Southern Africa

PK and drug interactions

• Key papers on methadone and ritonavir

Opportunistic infections and complications

• Single high dose fluconazole for oropharyngeal candidiasis

Treatment access

• FDA approval of generic ARVs

Basic science and immunology

• Control of a superinfecting virus in an elite controller

• Second-oldest HIV-1 sequence identified

• Why do we not yet have an HIV vaccine?

Other news

• Nobel Prize for medicine awarded to French discoverers of HIV

• Chinese AIDS activist wins human rights prize

On the web

• Abstracts from the 9th International Congress on Drug Therapy in HIV Infection

• Abstracts from AIDS Vaccine 2008

• Abstracts from BHIVA Autumn Conference, 9-10 October 2008

PDFs

• Volume 9 Number 11/12 November/December 2008 PDF